BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains a Market Perform rating on Bristol-Myers Squibb (NYSE:BMY) and raises the price target from $48 to $53.
September 27, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has maintained its Market Perform rating on Bristol-Myers Squibb and increased the price target from $48 to $53, indicating a positive outlook.
The increase in price target from $48 to $53 by BMO Capital suggests a positive outlook for Bristol-Myers Squibb, which could lead to a short-term increase in stock price. The Market Perform rating indicates a neutral stance, but the raised target shows confidence in potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100